A joint team of Polish and Brazilian researchers has developed a new machine learning model that can help improve cancer treatment planning by accurately predicting cancer severity. The model uses machine learning technology to identify specific proteins in tumor cells and predict how aggressive the tumors will be, allowing physicians to tailor cancer treatments for their patients.
With cancer diagnoses increasing globally, the medical industry is eager for tools that improve diagnosis and treatment. This model represents some of the most cutting-edge efforts to gain deeper insight into tumor development.
As machine learning and artificial intelligence grow more advanced by the day, they provide researchers with novel tools for detecting cancer and predicting its severity over time. The joint research team published its findings in the journal Cell Genomics. If the model, or a similar derivative, reaches widespread clinical use, doctors may soon be able to predict the severity of various cancers in individual patients, rather than relying solely on statistical averages. This could revolutionize treatment planning and improve survival outcomes following diagnosis.
The predictive model works by identifying certain proteins within a tumor cell and producing a “stemness index” that ranges from 0 to 1 (low aggressiveness to high aggressiveness). Cancers with a higher index typically grow more aggressively, resist treatment more effectively, and have a higher chance of recurrence. “Stemness” refers to how much tumor cells resemble pluripotent stem cells, a type of early-stage cell that can develop into nearly any type of human cell.
Malignant cancer cells generally become less similar to these stem cells as cancer progresses. Brazilian and Polish researchers used datasets from 11 cancer types provided by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) to develop the protein expression-based stemness index (PROTsi). By collecting proteomic data from over 200 pluripotent stem cells and integrating it with PROTsi, researchers were able to pinpoint the proteins responsible for tumor aggressiveness in 29 types of cancer.
This breakthrough underscores the transformative role of artificial intelligence in precision medicine. By giving physicians a clearer picture of how individual tumors behave, models like PROTsi can lead to faster diagnoses, earlier interventions, and better patient outcomes.
As cancer cases rise globally, integrating machine learning into oncology will be critical for advancing treatment. Tools that help predict tumor aggressiveness at the molecular level could soon become standard in clinical care, offering a smarter, more targeted approach to fighting cancer across the world.
As tumor aggressiveness becomes easier to predict, novel treatments from companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) can be administered sooner, increasing the chances of successful outcomes.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com
TinyGems is powered by IBN
